Drug Profile
Rociletinib companion diagnostic - Clovis Oncology/Qiagen
Alternative Names: CO-1686 companion diagnostic - Clovis Oncology/QiagenLatest Information Update: 20 Sep 2023
Price :
$50
*
At a glance
- Originator QIAGEN
- Developer Clovis Oncology; QIAGEN
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Non-small cell lung cancer
Most Recent Events
- 20 Sep 2023 Discontinued - Clinical-Phase-Unknown for Non-small cell lung cancer (Diagnosis) in Germany (unspecified route)
- 20 Sep 2023 Discontinued - Clinical-Phase-Unknown for Non-small cell lung cancer (Diagnosis) in USA (unspecified route)
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Diagnosis) in Germany